Cutaneous Manifestations of Unspecified Peripheral T-Cell Lymphoma May Be Indicative of Disease Activity and Predict Response to Therapy
| Autor: | Oleg E. Akilov, Michael K. Schowalter, Sara K. Story, Larisa J. Geskin |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Male
Cancer Research Systemic disease Pathology medicine.medical_specialty Response to therapy Paraneoplastic Syndromes medicine.drug_class T cell Romidepsin Central Nervous System Neoplasms Diagnosis in Oncology medicine Humans Aged business.industry Histone deacetylase inhibitor Lymphoma T-Cell Peripheral Exanthema medicine.disease Peripheral T-cell lymphoma Peripheral Lymphoma medicine.anatomical_structure Oncology business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 30:e283-e285 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2012.41.6644 |
| Popis: | Cutaneous manifestations of internal malignancy encompass both direct extension of tumor to the skin and indirect involvement (the so-called paraneoplastic syndromes). Direct cutaneous manifestations parallel systemic disease in progression, remission, and response to treatment. Peripheral T-cell lymphoma (PTCL) comprises a group of mature T-cell malignancies that together make up less than 15% of all non-Hodgkin's lymphoma; PTCL has been reported to directly involve the skin in a minority of cases.1 Unspecified PTCL (PTCL-u) makes up the majority of these lymphomas (60% to 70%).2 We report a patient with PTCL-u with secondary cutaneous involvement who was treated with a new histone deacetylase inhibitor, romidepsin (Istodax; Celgene, Summit, NJ). Because skin manifestations correlate with systemic disease activity, cutaneous manifestations can aid in monitoring of the systemic responses to therapy and can be a first warning sign of relapse. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|